Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
I'm PortAI, I can summarize articles.
Takeda Pharmaceutical's AI-developed psoriasis pill, zasocitinib, succeeded in late-stage studies, showing clear skin results in over half of patients after 16 weeks. Takeda plans to file for regulatory approval in 2026, aiming to compete in the crowded plaque psoriasis market. The pill could generate $3-6 billion in annual sales, filling a revenue gap post-Entyvio patent expiry. Acquired from Nimbus Therapeutics, zasocitinib was identified using AI, highlighting a growing trend in drug development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments